Suzuken (TSE:9987), What Is Behind The Fresh Attention?

Suzuken (TSE:9987) has drawn fresh attention after reporting first quarter earnings, updating its earnings outlook, and revising dividend guidance. This gives investors new information on profitability, cash returns, and near term expectations.

See our latest analysis for Suzuken.

The first quarter update and revised dividend outlook arrive after a weak share price patch for Suzuken, with the stock down 17.58% year to date on a share price basis but still showing a 75.49% five year total shareholder return. Recent earnings and guidance now give the market fresh information to reassess whether that longer term total shareholder return profile still matches the current risk and reward trade off.

If you are weighing Suzuken against other ideas in healthcare, this could be a good moment to see how it compares with companies in growth areas such as 8 healthcare AI stocks

Suzuken shares have retreated while both analyst targets and intrinsic value estimates sit higher, creating a wide valuation gap. Is this a genuine margin of safety, or a sign that fair value needs to be marked down?

Price-to-Earnings of 9.2x: Is it justified for Suzuken?

Suzuken currently trades on a P/E of 9.2x, while the last close sits at ¥5,123. On simple relative terms the stock appears cheaper than many peers in the healthcare space.

The P/E ratio compares the current share price with earnings per share. For a large pharmaceutical distributor such as Suzuken, this is a common way investors frame what they are paying for every unit of current earnings, especially when profits are established rather than highly volatile.

Here, the data suggests that Suzuken is trading at what is described as good value compared with both its direct peers and the broader JP Healthcare industry. The company is assessed as good value relative to the peer average P/E of 13.9x and the industry average of 14.7x. In addition, the estimated fair P/E for Suzuken is 17x, which is materially higher than the current 9.2x and points to a level the market could potentially move towards if sentiment and fundamentals align over time.

Explore the SWS fair ratio for Suzuken

Result: Price-to-Earnings of 9.2x (UNDERVALUED)

However, Suzuken still faces risks if earnings growth slows, or if healthcare policy changes affect pharmaceutical distribution margins and cash available for dividends.

Find out about the key risks to this Suzuken narrative.

Another view using the SWS DCF model

The P/E points to good value for Suzuken, but the SWS DCF model paints an even starker picture. On this view, Suzuken at ¥5,123 is trading at a 65.2% discount to an estimated future cash flow value of ¥14,718.67. That suggests deeper upside than the simple earnings multiple implies. Could that gap reflect a real opportunity? Or does it signal that cash flow assumptions may be too optimistic?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Suzuken for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 26 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With Suzuken showing both potential upsides and clear risks, this is a moment to look closely at the details and decide where you stand. To see the full picture of what the market sees as positives and concerns, review the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Suzuken?

If Suzuken has sharpened your appetite for opportunities, do not stop here. Use focused screeners to quickly surface stocks that better match your goals and risk comfort.

• Target potential bargains by scanning 26 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their financial profile.
• Strengthen your income focus by checking 30 dividend fortresses designed for investors who want higher yields alongside business resilience.
• Build confidence in your downside protection with the 59 resilient stocks with low risk scores so you can filter for companies that score well on risk measures before you commit capital.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com